Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis

2026-04-22 15:31:10 ET

The last time I spoke about Kyverna Therapeutics (KYTX), it was with a Seeking Alpha article entitled " Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing ." With respect to this article, I mentioned that this company had achieved the primary endpoint of its single-arm registrational phase 2 KYSA-8 study using miv-cel for the treatment of patients with stiff person syndrome [SPS]. Specifically, this therapy allowed it to meet the primary endpoint of the change from baseline in the timed 25-foot walk [T25FW] at 16 weeks in a statistically significant manner. At that time, I had a "Strong Buy" rating on this stock because of this feat that was achieved....

Read the full article on Seeking Alpha

For further details see: